FimmCyte
Deplete, Reprogram, Regenerate
FimmCyte was founded in 2022 and has 1 recorded funding round.
- Founded
- 2022
- Website
- fimmcyte.com
- Last Round
- Convertible NoteFeb 2024
- Rounds
- 1
Indexed holds 1 funding round for this company. The full record is or through the API.
About
FimmCyte is a Swiss biotech developing disease-modifying immunotherapies for chronic fibro-inflammatory diseases, with a focus on women's health.
Summary
FimmCyte is a Biotech company, founded in 2022. Its most recent funding was a Convertible Note round in Feb 2024.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Feb 2024
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/fimmcyte"><img src="https://indexed.vc/api/badge/company/fimmcyte" alt="FimmCyte on Indexed.vc" width="260" height="76" /></a>